×
About 12,110 results

ALLMedicine™ Pruritus Center

Research & Reviews  3,134 results

Complementary and integrative remedies in the treatment of chronic pruritus: A review o...
https://doi.org/10.1111/jocd.15094
Journal of Cosmetic Dermatology; Parvizi MM, Salami MH et. al.

May 18th, 2022 - Chronic pruritus is one of the most common conditions in dermatology as well as a common manifestation in many systemic diseases. Since the etiology of chronic pruritus remains somewhat unknown, hence, conventional medications may not always show ...

The Effectiveness of a Novel Skin Barrier Protectant in the Management of Acute Radiati...
https://doi.org/10.1097/01.ASW.0000826824.10120.fe
Advances in Skin & Wound Care; Robijns J, Van Bever L et. al.

May 17th, 2022 - Acute radiation dermatitis (ARD) is a frequent adverse effect in patients with cancer undergoing radiotherapy (RT). The aim of this case series is to evaluate the effect of a novel skin barrier protectant in patients with ARD. The skin barrier pro...

National safety surveillance of quadrivalent recombinant influenza vaccine in Taiwan du...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106408
Vaccine Tsai SY, Yeh TY et. al.

May 17th, 2022 - During the COVID-19 pandemic, the need for influenza vaccine significantly increased in the initial weeks of the 2020-2021 influenza vaccination campaign season in Taiwan. To meet this demand, the Taiwanese government therefore purchased additiona...

Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: A systematic ...
https://doi.org/10.1111/jdv.18221
Journal of the European Academy of Dermatology and Venere... Gael M, Adam T et. al.

May 16th, 2022 - Dupilumab has demonstrated a great reduction on chronic pruritus that is the hallmark of atopic dermatitis (AD). Underscoring relevant pathogenesis similarities emerging from AD, chronic idiopathic pruritus (CIP) and chronic prurigo (CP), several ...

Disulfiram Toxicity Medication
https://emedicine.medscape.com/article/814525-medication

May 16th, 2022 - Medication Summary The goals of pharmacotherapy are to reduce morbidity and to prevent complications. Next: GI decontaminant Class Summary These agents are empirically used to minimize systemic absorption of the toxin. Activated charcoal (Liqui-Ch...

see more →

Guidelines  6 results

Diagnosis and Management of Vulvar Skin Disorders: ACOG Practice Bulletin Summary, Numb...
https://doi.org/10.1097/AOG.0000000000003945
Obstetrics and Gynecology;

Jun 27th, 2020 - Vulvar skin disorders include a variety of inflammatory conditions of the vulva that also may affect the extragenital area. Pruritus and pain are two of the most common presenting symptoms in vulvar clinics (). Vulvovaginal symptoms often are chro...

Diagnosis and Management of Vulvar Skin Disorders: ACOG Practice Bulletin, Number 224.
https://doi.org/10.1097/AOG.0000000000003944
Obstetrics and Gynecology;

Jun 27th, 2020 - Vulvar skin disorders include a variety of inflammatory conditions of the vulva that also may affect the extragenital area. Pruritus and pain are two of the most common presenting symptoms in vulvar clinics (). Vulvovaginal symptoms often are chro...

British Association of Dermatologists' guidelines for the investigation and management ...
https://doi.org/10.1111/bjd.16117
The British Journal of Dermatology; Millington GWM, Collins A et. al.

Jan 24th, 2018 - British Association of Dermatologists' guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis, 2018.|2018|Millington GWM,Collins A,Lovell CR,Leslie TA,Yong ASW,|administration & dosage,co...

Clinical recommendation: pediatric lichen sclerosus.
https://doi.org/10.1016/j.jpag.2013.11.004
Journal of Pediatric and Adolescent Gynecology; Bercaw-Pratt JL, Boardman LA et. al.

Mar 8th, 2014 - Lichen sclerosus is a chronic inflammatory condition affecting the anogenital region that may present in the prepubertal or adolescent patient. Clinical presentations include significant pruritus, labial adhesions, and loss of pigmentation. Treatm...

Asia-Pacific consensus recommendations for endoscopic and interventional management of ...
https://doi.org/10.1111/jgh.12128
Journal of Gastroenterology and Hepatology; Rerknimitr R, Angsuwatcharakon P et. al.

Jan 29th, 2013 - Hilar cholangiocarcinoma (HCCA) is one of the most common types of hepatobiliary cancers reported in the world including Asia-Pacific region. Early HCCA may be completely asymptomatic. When significant hilar obstruction develops, the patient prese...

see more →

Drugs  730 results see all →

Clinicaltrials.gov  226 results

Dexmedetomine as Adjuvant for Spinal Anesthesia in Elective Cesarian Sections : a Pilot Study
https://clinicaltrials.gov/ct2/show/NCT05099055

May 12th, 2022 - 52 patients will be recruted for this study, and will be randomized in two equal groups. All the interventions carried out will be standardized. Medical care for patients will be the same as usual care, except for administration of dexmedetomidine...

The Effect of Low Level Light Therapy on Histamine- and Mucuna Pruriens-induced Pruritus in Healthy Volunteers
https://clinicaltrials.gov/ct2/show/NCT05369338

May 11th, 2022 - Rationale and relevance of the study Low-level light therapy (LLLT) is a method of photobiomodulation that involves the clinical application of light with wavelengths typically in the range of 600 to 1100 nm and with a typical power density of 5 m...

Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT04823130

May 10th, 2022 - AD patients: A 20-week Observation Period including 16 weeks of treatment for AD participants and a 4-week follow-up period Healthy subjects: 8 days observation period

Cyclosporine vs Steroids in DRESS
https://clinicaltrials.gov/ct2/show/NCT04988256

May 10th, 2022 - Current treatments for patients with drug reaction with eosinophilia and systemic symptoms (DRESS) include supportive care, steroids, cyclosporine and to a lesser extent, intravenous immunoglobulin (IVIG). Regarding IVIG, a recent case series sugg...

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
https://clinicaltrials.gov/ct2/show/NCT05050136

May 6th, 2022 - The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the diseas...

see more →

News  742 results

JDQ443 Demonstrates Early Efficacy Signals in KRAS G12C-Mutant Solid Tumors
https://www.onclive.com/view/jdq443-demonstrates-early-efficacy-signals-in-kras-g12c-mutant-solid-tumors

May 2nd, 2022 - The novel KRAS G12C inhibitor, JDQ443, demonstrated early efficacy signals and a tolerable safety profile in initial data from the dose-escalation portion of the phase 1b/2 KontRASt-01 (NCT04699188) trial presented at the 2022 AACR Annual Meeting....

Nab-Paclitaxel Plus Pembrolizumab Produces Promising Responses in Advanced Urothelial Cancer
https://www.onclive.com/view/nab-paclitaxel-plus-pembrolizumab-produces-promising-responses-in-advanced-urothelial-cancer

May 2nd, 2022 - The combination of nab-paclitaxel (Abraxane) and pembrolizumab (Keytruda) produced an encouraging overall response rate (ORR) with manageable safety in patients with advanced urothelial cancer who were refractory to platinum-based chemotherapy or ...

Topical Imiquimod as Good as Surgery for Vulvar Intraepithelial Neoplasia
https://www.medscape.com/viewarticle/972953

May 2nd, 2022 - NEW YORK (Reuters Health) - Topical imiquimod works just as well as surgery for the first-line treatment of women with vulvar high-grade squamous intraepithelial lesions (vHSILs) — a precancerous lesion commonly caused by human papillomavirus (HPV...

Substantial Toxic Effects of Breast Radiotherapy Often Missed
https://www.medscape.com/viewarticle/972981

Apr 29th, 2022 - Physicians often fail to detect symptoms of toxicity in women undergoing breast radiotherapy, a new analysis suggests. The study found that more than half of women with breast cancer experienced at least one substantial symptom during radiotherapy...

Durvalumab Plus Oleclumab or Monalizumab Induces Increased Response Rates in NSCLC
https://www.onclive.com/view/durvalumab-plus-oleclumab-or-monalizumab-induces-increased-response-rates-in-nsclc

Apr 28th, 2022 - Consolidation therapy with durvalumab (Imfinzi) and either oleclumab or monalizumab showed increased clinical benefits in patients with unresectable stage III non–small cell lung cancer (NSCLC), according to interim data from the phase 2 COAST stu...

see more →

Patient Education  6 results see all →